The following is a summary of “Naldemedine Use and Healthcare Resource Utilization in Patients treated with Opioid Analgesics for Chronic Non-Cancer Pain: Results of a Real-world Study in the USA,” ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

Harrow , a leading North American eyecare pharmaceutical company, announced the execution of a five-year strategic supply and development ("SSD") agreement for TRIESENCE® (triamcinolone acetonide ...

Agents Inducing CYP3A Metabolism: Consider alternative therapeutic agents with less enzyme induction potential in patients when rifampin or other strong CYP3A4 inducers are indicated for ...

Methods: The PBPK model for rifampicin, a potent CYP3A4 inducer, was developed and validated using human pharmacokinetic data. Subsequently, PBPK models for ‘victim’ drugs were constructed and ...

Drug Interactions: CAPLYTA should not be used with CYP3A4 inducers. Dose reduction is recommended for concomitant use with strong CYP3A4 inhibitors or moderate CYP3A4 inhibitors. Special Populations: ...

GlobalAir.com receives its data from NOAA, NWS, FAA and NACO, and Weather Underground. We strive to maintain current and accurate data. However, GlobalAir.com cannot guarantee the data received from ...

BOSTON, Feb. 18, 2025 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, ...

BOSTON, Feb. 18, 2025 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives ...